Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVE0897
- Development stage
- Discontinued
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AVE0897 is an orally active, small molecule dual antagonist of the vasopressin V1a and V1b receptors. Developed by Sanofi (formerly Sanofi-Aventis), the compound was designed to treat stress-related psychiatric disorders by modulating the hypothalamic-pituitary-adrenal (HPA) axis. Arginine vasopressin (AVP) plays a critical role in the regulation of the HPA axis, and overactivity of this system is often observed in patients with mood and anxiety disorders. By blocking both V1a and V1b receptors, AVE0897 was intended to provide a synergistic effect in reducing anxiety and depressive symptoms. Despite reaching Phase 2 clinical trials for major depressive disorder and generalized anxiety disorder, the development of AVE0897 was discontinued.
02
Targets
AVPR1A (Arginine vasopressin receptor 1A)AVPR1B (Vasopressin V1b Receptor)
Beyond the preview
Go deeper on AVE0897.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVE0897.